miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages

  Nielsen, Boye Schnack ^a   Balslev, Eva ^b   Poulsen, Tim ^b   Nielsen, Dorte ^b   Møller, Trine ^a   Mortensen, Christiane Ehlers ^b   Holmstrøm, Kim ^a   Høgdall, Estrid ^b  

^a BIONEER A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biomarker; Breast cancer; Her2; Mir 21; Prediction; Response; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MICRORNA 21; TRASTUZUMAB; KI 67 ANTIGEN; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CELL PROLIFERATION; FIBROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; ADULT; AGED; CANCER GRADING; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IN SITU HYBRIDIZATION; PATIENT CARE; TUMOR LOCALIZATION; UPREGULATION;

EID: 84904610164     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00207     Document Type: Article

References (54)

1. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research (2008) 14(24):8019-26. doi: 10.1158/1078-0432.ccr-08-0974.
2. Antoniotti S, Taverna D, Maggiora P, Sapei ML, Hynes NE, De Bortoli M. Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. British journal of cancer (1994) 70(6):1095-101.
3. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. Gene (1995) 159(1):19-27.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine (2001) 344(11):783-92. doi: 10.1056/NEJM200103153441101.
5. Nielsen DL, Kumler I, Palshof JA, Andersson M. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast (2013) 22(1):1-12. doi: 10.1016/j.breast.2012.09.008.
6. Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F, Wang X, He X, Zhao Y, Zhao Y. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. European journal of clinical investigation (2011) 41(11):1245-53. doi: 10.1111/j.1365-2362.2011.02535.x.
7. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNABiol (2011) 8(5).
8. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 299(4):425-36.
9. Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer ResTreat (2009) 117(1):131-40.
10. Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, Hansen U, Brunner N, Baker A, Moller S, Nielsen HJ. High levels of microRNA-21 in the stroma of colorectal cancers predict short diseasefree survival in stage II colon cancer patients. Clin Exp Metastasis (2011) 28(1):27-38.
11. Hermansen SK, Dahlrot RH, Nielsen BS, Hansen S, Kristensen BW. MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas. Journal of neuro-oncology (2013) 111(1):71-81. doi: 10.1007/s11060-012-0992-3.
12. Rask L, Balslev E, Jorgensen S, Eriksen J, Flyger H, Moller S, Hogdall E, Litman T, Nielsen BS. High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. APMIS (2011) 119(10):663-73.
13. Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR. MicroRNA-21 in Pancreatic Ductal Adenocarcinoma Tumor-Associated Fibroblasts Promotes Metastasis. PloS one (2013) 8(8):e71978. doi: 10.1371/journal.pone.0071978.
14. Nouraee N, Van Roosbroeck K, Vasei M, Semnani S, Samaei NM, Naghshvar F, Omidi AA, Calin GA, Mowla SJ. Expression, Tissue Distribution and Function of miR-21 in Esophageal Squamous Cell Carcinoma. PloS one (2013) 8(9):e73009. doi: 10.1371/journal.pone.0073009.
15. Kjaer-Frifeldt S, Hansen TF, Nielsen BS, Joergensen S, Lindebjerg J, Soerensen FB, dePont Christensen R, Jakobsen A, Danish Colorectal Cancer G. The prognostic importance of miR-21 in stage II colon cancer: a population-based study. British journal of cancer (2012) 107(7):1169-74. doi: 10.1038/bjc.2012.365.
16. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. European journal of cancer (2010) 46(2):298-311. doi: 10.1016/j.ejca.2009.10.027.
17. Haenisch S, Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics (2012) 4(4):369- doi: 10.2217/epi.12.39.
18. Kanakkanthara A, Miller JH. MicroRNAs: novel mediators of resistance to microtubuletargeting agents. Cancer treatment reviews (2013) 39(2):161-70. doi: 10.1016/j.ctrv.2012.07.005.
19. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. The Journal of biological chemistry (2011) 286(21):19127-37. doi: 10.1074/jbc.M110.216887.
20. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, Fishel R, Croce CM. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proceedings of the National Academy of Sciences of the United States of America (2010) 107(49):21098-103. doi: 10.1073/pnas.1015541107.
21. Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. British journal of cancer (2010) 103(10):1617-26. doi: 10.1038/sj.bjc.6605958.
22. Wang ZX, Lu BB, Wang H, Cheng ZX, Yin YM. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Archives of medical research (2011) 42(4):281-90. doi: 10.1016/j.arcmed.2011.06.008.
23. Tao J, Lu Q, Wu D, Li P, Xu B, Qing W, Wang M, Zhang Z, Zhang W. microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncology reports (2011) 25(6):1721- doi: 10.3892/or.2011.1245.
24. Chen Y, Tsai YH, Fang Y, Tseng SH. Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. Journal of pediatric surgery (2012) 47(10):1797-805. doi: 10.1016/j.jpedsurg.2012.05.013.
25. Yang SM, Huang C, Li XF, Yu MZ, He Y, Li J. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology (2013) 306:162-8. doi: 10.1016/j.tox.2013.02.014.
26. Mei M, Ren Y, Zhou X, Yuan XB, Han L, Wang GX, Jia Z, Pu PY, Kang CS, Yao Z. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technology in cancer research & treatment (2010) 9(1):77-86.
27. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 133(2):647-58.
28. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C, Gnyawali S, Shilo S, Nuovo GJ, Sen CK. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. CardiovascRes (2009) 82(1):21-9.
29. Correia NC, Girio A, Antunes I, Martins LR, Barata JT. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. European journal of cancer (2013). doi: 10.1016/j.ejca.2013.08.017.
30. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer cell (2004) 6(2):117-27. doi: 10.1016/j.ccr.2004.06.022.
31. Ostman A. The tumor microenvironment controls drug sensitivity. Nature medicine (2012) 18(9):1332-4. doi: 10.1038/nm.2938.
32. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes & development (2011) 25(23):2465-79. doi: 10.1101/gad.180331.111.
33. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, Fein M, Rasch MG, Tan YX, Qiu J, Park J, Sinha P, Bissell MJ, Frengen E, Werb Z, Egeblad M. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer cell (2012) 21(4):488-503. doi: 10.1016/j.ccr.2012.02.017.
34. Alkhateeb AA, Leitzel K, Ali SM, Campbell-Baird C, Evans M, Fuchs EM, Kostler WJ, Lipton A, Connor J. Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy. PloS one (2012) 7(12):e51379. doi: 10.1371/journal.pone.0051379.
35. Nielsen BS, Holmstrom K. Combined microRNA in situ hybridization and immunohistochemical detection of protein markers. Methods in molecular biology (2013) 986:353-65. doi: 10.1007/978-1-62703-311-4_22.
36. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA (2008) 14(11):2348-60.
37. Ozgun A, Karagoz B, Bilgi O, Tuncel T, Baloglu H, Kandemir EG. MicroRNA-21 as an indicator of aggressive phenotype in breast cancer. Onkologie (2013) 36(3):115-8. doi: 10.1159/000348678.
38. Hong L, Han Y, Zhang Y, Zhang H, Zhao Q, Wu K, Fan D. MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert opinion on therapeutic targets (2013) 17(9):1073-80. doi: 10.1517/14728222.2013.819853.
39. Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer biology & therapy (2010) 10(12):1224-32.
40. Sempere LF, Martinez P, Cole C, Baguna J, Peterson KJ. Phylogenetic distribution of microRNAs supports the basal position of acoel flatworms and the polyphyly of Platyhelminthes. EvolDev (2007) 9(5):409-15.
41. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, Olson EN. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer cell (2010) 18(3):282-93. doi: 10.1016/j.ccr.2010.08.013.
42. Ma X, Kumar M, Choudhury SN, Becker Buscaglia LE, Barker JR, Kanakamedala K, Liu MF, Li Y. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. ProcNatlAcadSciUSA (2011) 108(25):10144-9.
43. Ma X, Choudhury SN, Hua X, Dai Z, Li Y. Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway. Carcinogenesis (2013) 34(6):1216-23. doi: 10.1093/carcin/bgt044.
44. Huang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, Brincat A, Horiuchi D, Lebbink RJ, Mo YY, Goga A, McManus MT. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. The Journal of biological chemistry (2009) 284(27):18515-24. doi: 10.1074/jbc.M109.006676.
45. Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathology international (1999) 49(12):1067-77.
46. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, Honjo T. Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene (1995) 166(2):297-301.
47. Jurisicova A, Latham KE, Casper RF, Casper RF, Varmuza SL. Expression and regulation of genes associated with cell death during murine preimplantation embryo development. Molecular reproduction and development (1998) 51(3):243-53. doi: 10.1002/(SICI)1098-2795(199811)51:3<243::AIDMRD3> 3.0.CO;2-P.
48. Yang HS, Jansen AP, Nair R, Shibahara K, Verma AK, Cmarik JL, Colburn NH. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene (2001) 20(6):669-76. doi: 10.1038/sj.onc.1204137.
49. Nieves-Alicea R, Colburn NH, Simeone AM, Tari AM. Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression. Breast cancer research and treatment (2009) 114(2):203-9. doi: 10.1007/s10549-008-9993-5.
50. Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H, Afonja O. Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncology reports (2007) 18(6):1387-93.
51. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis (2007) 28(7):1379-86. doi: 10.1093/carcin/bgm052.
52. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL, Naidu S, Wei G, Sharma SM, Stephens JA, Fernandez SA, Gurcan MN, Weinstein MB, Barsky SH, Yee L, Rosol TJ, Stromberg PC, Robinson ML, Pepin F, Hallett M, Park M, Ostrowski MC, Leone G. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature (2009) 461(7267):1084-91.
53. Wallace JA, Li F, Leone G, Ostrowski MC. Pten in the breast tumor microenvironment: modeling tumor-stroma coevolution. Cancer research (2011) 71(4):1203-7. doi: 10.1158/0008-5472.CAN-10-3263.
54. Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J, Arribas J. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. The EMBO journal (2006) 25(13):3234-44. doi: 10.1038/sj.emboj.7601191.